CommentaryDual pathway inhibition of coagulation and inflammation with rivaroxaban: a new therapy paradigm against atherosclerosisTesta, Alberto1; Morello, Alberto MD2,3; Corcione, Nicola MD2,3; Biondi-Zoccai, Giuseppe MD, MStat4,5 Author Information 1Sapienza School for Advanced Studies, Sapienza University of Rome, Rome, Italy 2Unità Operativa di Interventistica Cardiovascolare, Pineta Grande Hospital, Castel Volturno, Italy 3Unità Operativa di Emodinamica, Santa Lucia Hospital, San Giuseppe Vesuviano, Italy 4Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy 5Mediterranea Cardiocentro, Napoli, Italy. Corresponding author: Prof. Giuseppe Biondi-Zoccai, Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. Email: [email protected]. Funding: None Disclosure: Giuseppe Biondi-Zoccai has consulted for Balmed, Cardionovum, Crannmedical, Eukon, Innovheart, Guidotti, Meditrial, Microport, Opsens Medical, Replycare, Teleflex, and Terumo. All other authors report no conflict of interest. Journal of Cardiovascular Pharmacology ():10.1097/FJC.0000000000001385, January 12, 2023. | DOI: 10.1097/FJC.0000000000001385 Free PAP Metrics Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.